BSE filing, NSE: RTFL. Summary written from the filing by ALFA Finder's alert engine.
Real Touch Finance Ltd: key numbers
- Share price
- ₹32.23
- Market cap
- ₹40.91 Cr
- Revenue (annual)
- ₹39.17 Cr
- Net profit (annual)
- ₹5.19 Cr
- P/E (TTM)
- 8.2×Sector 19.7×
- Promoter holding
- 54.12%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Real Touch Finance Ltd
All →Real Touch Finance Other Announcement
The company filed its quarterly shareholding pattern under Regulation 31(1)(b) for the period ended September 30, 2026, as required by SEBI regulations.
Real Touch Finance Management Change
Real Touch Finance Limited appointed Mrs. Mathangi G as Chief Financial Officer effective October 9, 2026. The board also proposed two new director appointments pending RBI approval.
Real Touch Finance Management Change
Real Touch Finance Limited announced the re-appointment of Mr. Somnath Sarkar as Independent Director for 60 months. Mr. Angalappan Anandakumar's designation was also changed to Executive Director.
Real Touch Finance Annual General Meeting
Real Touch Finance Limited concluded its 41st Annual General Meeting on September 26, 2026, where members transacted various ordinary and special business items.
Real Touch Finance Other Announcement
Real Touch Finance is notifying shareholders with unregistered email addresses about the web links for the 41st AGM notice and the Annual Report.
Real Touch Finance Annual General Meeting
Real Touch Finance Limited submitted its 41st Annual Report for FY 2025-26. It also released the formal notice convening the company's 41st Annual General Meeting for September 2026.
Other regulatory approval announcements
All →Shalby Regulatory Approval
Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.
Elantas Beck India Regulatory Approval
Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.
Kalyani Cast-Tech Regulatory Approval
Kalyani Cast-Tech received RDSO Stage-I concept design approval for its new container-carrying wagon under PWDA. Stage-II detailed design approval is still required, subject to dynamics simulation conditions.
Mukka Proteins Regulatory Approval
Mukka Proteins received a US FDA facility registration certificate, valid October 1, 2026 to December 31, 2027. The company says the registration supports its engagement with US customers and markets.
- Execution
- October 1, 2026 to December 31, 2027
Canara Bank Regulatory Approval
Canara Bank received RBI permission to exercise the call option on its Basel III AT1 bonds (ISIN INE476A08134) of Rs.1,500 Crore. The bank is now in process of exercising the call as per the issue terms.
- Value
- ₹1,500 Cr
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.